MedPath

Cisatracurium

Generic Name
Cisatracurium
Brand Names
Nimbex
Drug Type
Small Molecule
Chemical Formula
C53H72N2O12
CAS Number
96946-41-7
Unique Ingredient Identifier
QX62KLI41N

Overview

Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate. Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.. Cisatracurium acts on cholinergic receptors, blocking neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine. Cisatracurium is an R-cis-R-cis isomer of atracurium and has approximately 3 times its neuromuscular blocking potency. Compared to atracurium, cisatracurium produces a lower degree of histamine release.

Background

Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate. Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.. Cisatracurium acts on cholinergic receptors, blocking neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine. Cisatracurium is an R-cis-R-cis isomer of atracurium and has approximately 3 times its neuromuscular blocking potency. Compared to atracurium, cisatracurium produces a lower degree of histamine release.

Indication

Cisatracurium is indicated as an adjunct to general anesthesia to facilitate tracheal intubation in adults and pediatric patients 1 month to 12 years of age. Cisatracurium is also indicated to provide skeletal muscle relaxation during surgery in adults and pediatric patients 2 to 12 years of age as a bolus or infusion maintenance and for mechanical ventilation in the ICU in adults.

Associated Conditions

No associated conditions information available.

FDA Approved Products

Cisatracurium Besylate
Manufacturer:Meitheal Pharmaceuticals Inc.
Route:INTRAVENOUS
Strength:10 mg in 5 mL
Approved: 2023/04/20
NDC:71288-712
Cisatracurium Besylate
Manufacturer:Meitheal Pharmaceuticals Inc.
Route:INTRAVENOUS
Strength:20 mg in 10 mL
Approved: 2023/04/20
NDC:71288-714
Cisatracurium Besylate
Manufacturer:Meitheal Pharmaceuticals Inc.
Route:INTRAVENOUS
Strength:200 mg in 20 mL
Approved: 2023/04/20
NDC:71288-713
cisatracurium besylate
Manufacturer:Civica, Inc.
Route:INTRAVENOUS
Strength:2 mg in 1 mL
Approved: 2022/04/13
NDC:72572-066
Cisatracurium Besylate
Manufacturer:Piramal Healthcare UK Limited
Route:INTRAVENOUS
Strength:2 mg in 1 mL
Approved: 2022/01/18
NDC:24584-1111

Singapore Approved Products

Nimbex Forte Injection 150 mg/30 ml
Manufacturer:GlaxoSmithKline Manufacturing S.p.A.
Form:INJECTION, SOLUTION
Strength:150 mg/30 ml
Online:Yes
Approved: 2013/02/05
Approval:SIN14310P
Nimbex Injection 2 mg/ml
Manufacturer:GlaxoSmithKline Manufacturing S.p.A.
Form:INJECTION, SOLUTION
Strength:2 mg/ml
Online:Yes
Approved: 2013/02/05
Approval:SIN14309P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath